Intravascular Lithotripsy for Heart Disease

Not currently recruiting at 35 trial locations
RR
LD
Overseen ByLesli DeSimone
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a treatment called Shockwave Intravascular Lithotripsy to determine its safety and effectiveness for individuals with certain types of heart disease. The focus is on treating blocked heart arteries, known as coronary artery lesions, that have hardened due to calcium buildup. Individuals who have experienced stable chest pain or have recovered from a recent heart event might be suitable candidates. The researchers aim to discover if this treatment can help open arteries before placing a stent, a tiny tube used to keep arteries open. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could enhance heart disease treatments.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, you must be able to tolerate antiplatelet or anticoagulation therapy as per guidelines, and if you have taken warfarin recently, your INR (a blood test) must be checked.

What prior data suggests that the Shockwave Intravascular Lithotripsy is safe for treating coronary artery lesions?

Research has shown that the Shockwave Intravascular Lithotripsy (IVL) system is generally safe for treating hardened areas in the heart's arteries. Early studies have found that patients usually handle the procedure well. Initial results from using the Shockwave Javelin Coronary IVL Catheter indicated it is both safe and effective for treating tough artery blockages.

Additionally, one study found that patients experienced lasting positive results and safety over time. These findings are encouraging, but it's important to remember that all medical treatments can have risks. Participants in this trial will contribute to a better understanding of the treatment's safety.12345

Why are researchers excited about this trial?

Shockwave Intravascular Lithotripsy is unique because it uses sound waves to break up calcified plaques in the coronary arteries, which is different from the standard methods like balloon angioplasty or stenting. Most treatments for coronary artery disease rely on physically expanding the artery, but this treatment targets the underlying calcification directly, potentially reducing the risk of further complications. Researchers are excited about this technique because it offers a less invasive option that could lead to better outcomes for patients with severely calcified arteries.

What evidence suggests that the Shockwave Intravascular Lithotripsy is effective for heart disease?

Research has shown that the Shockwave Intravascular Lithotripsy (IVL) system, which participants in this trial will receive, effectively treats narrowed heart arteries hardened by calcium buildup. Early studies indicate that the IVL system safely breaks down these calcium blockages, facilitating stent insertion. Initial findings suggest the procedure is safe and offers good long-term results, with stents maintaining their effectiveness over time. Patients treated with this method demonstrated significant improvement in blood flow through the treated arteries. This new approach targets tough calcium deposits that traditional methods find difficult to treat.13456

Who Is on the Research Team?

RW

Robert W Yeh, M.D., M.Sc, M.B.A

Principal Investigator

Beth Israel Deaconess Medical Center

JC

James C Spratt, MD, MB, ChB, FRCP, FESC, FACC

Principal Investigator

St. George's University NHS Trust

RF

Robert F Riley, MD, MS, FACC, FAHA, FSCAI

Principal Investigator

Overlake Medical Center & Clinics

Are You a Good Fit for This Trial?

The FORWARD CAD IDE Study is for adults over 18 with heart disease, specifically those with calcified, stenotic de novo coronary artery lesions. Participants must have a life expectancy of more than a year, be able to follow the study's procedures, and have left ventricular ejection fraction (LVEF) greater than 30%. They should not have had previous successful interventions on the lesion and must consent to participate.

Inclusion Criteria

I am willing and able to follow all study requirements.
I have heart disease that's stable or treated after a recent heart attack.
I have signed, or my legal representative has signed, the consent form to participate in the study.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive treatment with the Shockwave Javelin Coronary IVL Catheter for calcified coronary artery lesions

Peri-procedural
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on freedom from major adverse cardiac events (MACE) within 30 days

30 days

What Are the Treatments Tested in This Trial?

Interventions

  • Shockwave Intravascular Lithotripsy
Trial Overview This study tests the Shockwave Intravascular Lithotripsy (IVL) System using Javelin Coronary IVL Catheter for treating hardened blockages in heart arteries before placing stents. It's a single-arm trial meaning all participants receive the same treatment without comparison to another group or placebo.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Shockwave Javelin Coronary IVL CatheterExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Shockwave Medical, Inc.

Lead Sponsor

Trials
38
Recruited
10,200+

Citations

Johnson & Johnson One Year Data Demonstrate Durable ...Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking ...
Shockwave Medical Enrolls First Patient in FORWARD ...Investigators in the study will assess the safety and effectiveness of the Shockwave Javelin Coronary IVL Catheter for the treatment of calcified, difficult-to ...
Study Details | NCT06662500 | FORWARD CAD IDE StudyThe Shockwave Javelin Coronary IVL Catheter will be used to treat subjects with moderate-to-severely calcified, stenotic de novo coronary artery lesions ...
First-in-human data highlight IVL's potential to treat more ...Early data on Shockwave Medical's Coronary IVL Catheter. Shockwave Medical's Javelin Coronary IVL Catheter appears to be a safe and effective ...
Initial Longer-term Outcomes Under Imaging With ...This recent study dives into mid-term angiographic and intracoronary imaging results post IVL usage, showing durable results with preserved stent parameters ...
Shockwave Medical Enrolls First Patient in FORWARD CAD ...Investigators in the study will assess the safety and effectiveness of the Shockwave Javelin Coronary IVL Catheter for the treatment of calcified, difficult-to ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security